The objective of this application is to develop a prostate cancer research program that will become part of the NCI funded cancer center support grant held by the Robert H. Lurie Cancer Center at Northwestern University. The overall goal is to develop new strategies in the prevention, early diagnosis, treatment and rehabilitation of prostate cancer. The proposed program will be implemented under the leadership of Chung Lee, PhD and James M. Kozlowski, MD. An internal advisory committee will be assembled consisting of senior members of the Lurie Cancer Center. External advisors/consultants will be selected on an ad hoc basis. The proposed program has identified a nucleus of investigators interested in prostate cancer research and, from this nucleus, four pilot projects have been identified for funding for the first year of this program. The program will also recruit new investigators to compliment the existing expertise in prostate cancer research. Opportunities to provide enhanced interactions among investigators will be incorporated by way of retreats and monthly prostate cancer scientific conferences. In addition to all of the resources available to prostate cancer investigators, the Lurie Cancer Center has designated a prostate cancer research laboratory which will serve as a technical resource center to facilitate prostate cancer research. The proposed program will take advantage of three hospitals affiliated with the Lurie Cancer Center for prostate cancer patient population. These hospitals are Northwestern Memorial Hospital, VA Lakeside Medical Center and Evanston Hospital. Every effort will be made to recruit minority populations for various studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21CA069851-04
Application #
2769844
Study Section
Special Emphasis Panel (SRC (06))
Project Start
1995-09-30
Project End
2000-08-31
Budget Start
1998-09-01
Budget End
2000-08-31
Support Year
4
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Northwestern University at Chicago
Department
Urology
Type
Schools of Medicine
DUNS #
005436803
City
Chicago
State
IL
Country
United States
Zip Code
60611
Bhattacharyya, Rumi S; Stern, Paula H (2003) IGF-I and MAP kinase involvement in the stimulatory effects of LNCaP prostate cancer cell conditioned media on cell proliferation and protein synthesis in MC3T3-E1 osteoblastic cells. J Cell Biochem 90:925-37
Gann, P H; Chatterton, R T; Lee, C (2001) Peptide growth factors as biomarkers of prostate cancer risk. Epidemiol Rev 23:67-71
Kassen, A E; Sensibar, J A; Sintich, S M et al. (2000) Autocrine effect of DHT on FGF signaling and cell proliferation in LNCaP cells: role of heparin/heparan-degrading enzymes. Prostate 44:124-32
Engel, J D; Kundu, S D; Yang, T et al. (1999) Transforming growth factor-beta type II receptor confers tumor suppressor activity in murine renal carcinoma (Renca) cells. Urology 54:164-70
Gann, P H; Klein, K G; Chatterton, R T et al. (1999) Growth factors in expressed prostatic fluid from men with prostate cancer, BPH, and clinically normal prostates. Prostate 40:248-55
Sintich, S M; Lamm, M L; Sensibar, J A et al. (1999) Transforming growth factor-beta1-induced proliferation of the prostate cancer cell line, TSU-Pr1: the role of platelet-derived growth factor. Endocrinology 140:3411-5
Sintich, S M; Steinberg, J; Kozlowski, J M et al. (1999) Cytotoxic sensitivity to tumor necrosis factor-alpha in PC3 and LNCaP prostatic cancer cells is regulated by extracellular levels of SGP-2 (clusterin). Prostate 39:87-93
Zhu, N; Pewitt, E B; Cai, X et al. (1998) Calreticulin: an intracellular Ca++-binding protein abundantly expressed and regulated by androgen in prostatic epithelial cells. Endocrinology 139:4337-44
Kundu, S D; Kim, I Y; Zelner, D et al. (1998) Absence of expression of transforming growth factor-beta type II receptor is associated with an aggressive growth pattern in a murine renal carcinoma cell line, Renca. J Urol 160:1883-8
Okamoto, M; Lee, C; Oyasu, R (1997) Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res 57:141-6

Showing the most recent 10 out of 17 publications